InterPAD - DETAILS

simvastatin, 79902-63-9, Zocor, Synvinolin, Sinvacor, Denan, Lipex, MK-733, Sivastin, Lodales, Cholestat, Simvastatine, Colemin, Medipo, Pantok, Simovil, Labistatin, Simvastatina, Simvastatinum, Velostatin, Coledis, Corolin, Nivelipol, Rendapid, Vasotenal, Zorced, Rechol, Zocord, Simvastatin (Zocor), Simvastatin lactone, Lipovas, Simcard, Simvacor, Simvoget, Simlup, Zosta, MK-0733, Simvastatinum [Latin], (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, DRG-0320, CCRIS 7558, MK 0733, HSDB 7208, UNII-AGG2FN16EV, AGG2FN16EV, 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one, Statin, NSC-758706, L 644128-000U, BRN 4768037, CHEBI:9150, DTXSID0023581, C10AA01, DTXCID103581, (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, SIMCOR COMPONENT SIMVASTATIN, Simvastatin [USAN:USP:INN:BAN], VYTORIN COMPONENT SIMVASTATIN, MFCD00072007, NSC633782, NSC 758706, [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate, Simvastatinum (Latin), Simvastatine [French], Simvastatina [Spanish], SIMVASTATIN (MART.), SIMVASTATIN [MART.], SIMVASTATIN (USP-RS), SIMVASTATIN [USP-RS], Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-, SIMVASTATIN (EP MONOGRAPH), SIMVASTATIN [EP MONOGRAPH], SIMVASTATIN (USP MONOGRAPH), SIMVASTATIN [USP MONOGRAPH], Simvastatin (USAN:USP:INN:BAN), Simvast CR, (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate, SMR000718785, Zocor (TN), Simvastatin & Primycin, MK733, SR-05000001894, MK 733, Kolestevan, Lipinorm, Modutrol, Simvotin, Sinvascor, Valemia, Eucor, Nor-Vastina, Simvastatin,(S), simvastatin predrug, (+)-Simvastatin, NCGC00016940-01, inactive simvastatin, 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one, TNP00259, Prestwick_171, Simvastatin- Bio-X, CAS-79902-63-9, FLOLIPID, KS-1113, Spectrum_001717, SpecPlus_000895, SIMVASTATIN [MI], Prestwick0_000865, Prestwick1_000865, Prestwick2_000865, Prestwick3_000865, Spectrum2_001671, Spectrum3_000669, Spectrum4_000632, Spectrum5_001428, SIMVASTATIN [INN], SIMVASTATIN [JAN], SIMVASTATIN [HSDB], SIMVASTATIN [USAN], SIMVASTATIN [VANDF], SCHEMBL2471, CHEMBL1064, BSPBio_000909, BSPBio_002337, KBioGR_001244, KBioSS_002197, SIMVASTATIN [WHO-DD], MLS001304029, MLS001333077, MLS001333078, MLS002154038, MLS006011866, BIDD:GT0769, DivK1c_006991, SPECTRUM1504236, SPBio_001881, SPBio_002830, BPBio1_001001, GTPL2955, Simvastatin (JP17/USP/INN), Simvastatin, analytical standard, BCBcMAP01_000007, KBio1_001935, KBio2_002197, KBio2_004765, KBio2_007333, KBio3_001557, RYMZZMVNJRMUDD-HGQWONQESA-, SIMVASTATIN [ORANGE BOOK], HMS1570N11, HMS1922H13, HMS2089D12, HMS2093E06, HMS2097N11, HMS2231N22, HMS3259B12, HMS3412P08, HMS3676P08, HMS3714N11, HMS3884G10, Pharmakon1600-01504236, BUTANOIC ACID, 2,2-DIMETHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.,3.ALPHA.,7.BETA.,8.BETA.(2S*,4S*),8A.BETA.))-, Tox21_110696, Tox21_300400, BBL024390, BDBM50139181, CCG-39069, NSC758706, s1792, STK801938, AKOS005111006, AKOS015842733, SIMVASTATIN COMPONENT OF SIMCOR, Simvastatin, >=97% (HPLC), solid, Tox21_110696_1, AC-1530, DB00641, NC00719, NSC-633782, SIMVASTATIN COMPONENT OF VYTORIN, MRF-0000729, NCGC00017324-01, NCGC00017324-02, NCGC00017324-03, NCGC00017324-04, NCGC00017324-05, NCGC00017324-07, NCGC00017324-08, NCGC00017324-09, NCGC00254418-01, 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, BS164407, HY-17502, SBI-0206773.P001, Simvastatin 100 microg/mL in Acetonitrile, NS00008782, S0509, EN300-52503, D00434, AB00053395-07, AB00053395-08, AB00053395-10, AB00053395_11, AB00053395_13, A839783, Q670131, SR-05000001894-1, SR-05000001894-2, BRD-K22134346-001-05-8, BRD-K22134346-001-11-6, BRD-K22134346-001-15-7, Z754918914, Simvastatin, British Pharmacopoeia (BP) Reference Standard, Simvastatin, European Pharmacopoeia (EP) Reference Standard, Simvastatin, United States Pharmacopeia (USP) Reference Standard, Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material, Simvastatin for peak identification, European Pharmacopoeia (EP) Reference Standard, (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbu, (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl 2,2-dimethylbutanoate, InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

Name	Simvastatin
PubChem CID	54454
Molecular Weight	418.6g/mol
Synonyms	simvastatin, 79902-63-9, Zocor, Synvinolin, Sinvacor, Denan, Lipex, MK-733, Sivastin, Lodales, Cholestat, Simvastatine, Colemin, Medipo, Pantok, Simovil, Labistatin, Simvastatina, Simvastatinum, Velostatin, Coledis, Corolin, Nivelipol, Rendapid, Vasotenal, Zorced, Rechol, Zocord, Simvastatin (Zocor), Simvastatin lactone, Lipovas, Simcard, Simvacor, Simvoget, Simlup, Zosta, MK-0733, Simvastatinum [Latin], (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, DRG-0320, CCRIS 7558, MK 0733, HSDB 7208, UNII-AGG2FN16EV, AGG2FN16EV, 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one, Statin, NSC-758706, L 644128-000U, BRN 4768037, CHEBI:9150, DTXSID0023581, C10AA01, DTXCID103581, (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, SIMCOR COMPONENT SIMVASTATIN, Simvastatin [USAN:USP:INN:BAN], VYTORIN COMPONENT SIMVASTATIN, MFCD00072007, NSC633782, NSC 758706, [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate, Simvastatinum (Latin), Simvastatine [French], Simvastatina [Spanish], SIMVASTATIN (MART.), SIMVASTATIN [MART.], SIMVASTATIN (USP-RS), SIMVASTATIN [USP-RS], Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S,4S),8abeta))-, SIMVASTATIN (EP MONOGRAPH), SIMVASTATIN [EP MONOGRAPH], SIMVASTATIN (USP MONOGRAPH), SIMVASTATIN [USP MONOGRAPH], Simvastatin (USAN:USP:INN:BAN), Simvast CR, (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate, SMR000718785, Zocor (TN), Simvastatin & Primycin, MK733, SR-05000001894, MK 733, Kolestevan, Lipinorm, Modutrol, Simvotin, Sinvascor, Valemia, Eucor, Nor-Vastina, Simvastatin,(S), simvastatin predrug, (+)-Simvastatin, NCGC00016940-01, inactive simvastatin, 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one, TNP00259, Prestwick_171, Simvastatin- Bio-X, CAS-79902-63-9, FLOLIPID, KS-1113, Spectrum_001717, SpecPlus_000895, SIMVASTATIN [MI], Prestwick0_000865, Prestwick1_000865, Prestwick2_000865, Prestwick3_000865, Spectrum2_001671, Spectrum3_000669, Spectrum4_000632, Spectrum5_001428, SIMVASTATIN [INN], SIMVASTATIN [JAN], SIMVASTATIN [HSDB], SIMVASTATIN [USAN], SIMVASTATIN [VANDF], SCHEMBL2471, CHEMBL1064, BSPBio_000909, BSPBio_002337, KBioGR_001244, KBioSS_002197, SIMVASTATIN [WHO-DD], MLS001304029, MLS001333077, MLS001333078, MLS002154038, MLS006011866, BIDD:GT0769, DivK1c_006991, SPECTRUM1504236, SPBio_001881, SPBio_002830, BPBio1_001001, GTPL2955, Simvastatin (JP17/USP/INN), Simvastatin, analytical standard, BCBcMAP01_000007, KBio1_001935, KBio2_002197, KBio2_004765, KBio2_007333, KBio3_001557, RYMZZMVNJRMUDD-HGQWONQESA-, SIMVASTATIN [ORANGE BOOK], HMS1570N11, HMS1922H13, HMS2089D12, HMS2093E06, HMS2097N11, HMS2231N22, HMS3259B12, HMS3412P08, HMS3676P08, HMS3714N11, HMS3884G10, Pharmakon1600-01504236, BUTANOIC ACID, 2,2-DIMETHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.,3.ALPHA.,7.BETA.,8.BETA.(2S,4S),8A.BETA.))-, Tox21_110696, Tox21_300400, BBL024390, BDBM50139181, CCG-39069, NSC758706, s1792, STK801938, AKOS005111006, AKOS015842733, SIMVASTATIN COMPONENT OF SIMCOR, Simvastatin, >=97% (HPLC), solid, Tox21_110696_1, AC-1530, DB00641, NC00719, NSC-633782, SIMVASTATIN COMPONENT OF VYTORIN, MRF-0000729, NCGC00017324-01, NCGC00017324-02, NCGC00017324-03, NCGC00017324-04, NCGC00017324-05, NCGC00017324-07, NCGC00017324-08, NCGC00017324-09, NCGC00254418-01, 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, BS164407, HY-17502, SBI-0206773.P001, Simvastatin 100 microg/mL in Acetonitrile, NS00008782, S0509, EN300-52503, D00434, AB00053395-07, AB00053395-08, AB00053395-10, AB00053395_11, AB00053395_13, A839783, Q670131, SR-05000001894-1, SR-05000001894-2, BRD-K22134346-001-05-8, BRD-K22134346-001-11-6, BRD-K22134346-001-15-7, Z754918914, Simvastatin, British Pharmacopoeia (BP) Reference Standard, Simvastatin, European Pharmacopoeia (EP) Reference Standard, Simvastatin, United States Pharmacopeia (USP) Reference Standard, Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material, Simvastatin for peak identification, European Pharmacopoeia (EP) Reference Standard, (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbu, (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, (1S-(1alpha,3alpha,7beta,8beta(2S,4S),8abeta))-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl 2,2-dimethylbutanoate, InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
Drug Type	Small molecule
Formula	C₂₅H₃₈O₅
SMILES	CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
InChI	1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
InChIKey	RYMZZMVNJRMUDD-HGQWONQESA-N
CAS Number	79902-63-9
ChEMBL ID	CHEMBL1064
ChEBI ID	CHEBI:9150
TTD ID	D0H0ND
Drug Bank ID	DB00641
KEGG ID	D00434
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Thymoquinone, Simvastatin
Partner Name	Thymoquinone
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	It was concluded that the combined effect of simvastatin and thymoquinone stimulates apoptosis in breast cancer cells.

Pair Name	Geraniol, Simvastatin
Partner Name	Geraniol
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Cell proliferation
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
Result	Our results demonstrate that the combination of simvastatin and geraniol synergistically inhibited cholesterol biosynthesis and proliferation of Hep G2 cell line, contributing to a better understanding of the action of a component of essential oils targeting a complex metabolic pathway, which would improve the use of drugs or their combination in the fight against cancer and/or cardiovascular diseases.

Pair Name	Bergamottin, Simvastatin
Partner Name	Bergamottin
Disease Info	[ICD-11: 2A20.1]	Chronic myelogenous leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	BIRC2	hsa329
	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCND1	hsa595
	Up-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	NFKB1	hsa4790
	Up-regulation	Expression	NFKBIA	hsa4792
	Up-regulation	Expression	PSMD9	hsa5715
	Up-regulation	Expression	RELA	hsa5970
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	KBM-5	Chronic myelogenous leukemia	Homo sapiens (Human)	CVCL_0373
In Vitro Model	AIP WT MEF	Healthy	Mus musculus (Mouse)	CVCL_UJ03
Result	Discussion and conclusion Our results provide novel insight into the role of SV and BGM in potentially preventing and treating cancer through modulation of NF-κB signalling pathway and its regulated gene products.

Pair Name	Gamma-Tocotrienol, Simvastatin
Partner Name	Gamma-Tocotrienol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	NCI-ADR-RES	High grade ovarian serous adenocarcinoma	Homo sapiens (Human)	CVCL_1452
In Vitro Model	MCF-7/TAMR-1	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_M436
Result	Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol

No.	Title	Href
1	Evaluation of Enhanced Cytotoxicity Effect of Repurposed Drug Simvastatin/ Thymoquinone Combination against Breast Cancer Cell Line. Cardiovasc Hematol Agents Med Chem. 2023 Oct 27. doi: 10.2174/0118715257259037231012182741.	`Click`
2	Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line. Cell Biochem Funct. 2011 Aug;29(6):452-8. doi: 10.1002/cbf.1772.	`Click`
3	Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-κB signalling pathway in human chronic myelogenous leukaemia. Pharm Biol. 2016 Oct;54(10):2050-60. doi: 10.3109/13880209.2016.1141221.	`Click`
4	Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol. Cancer Lett. 2013 Jan 28;328(2):285-96. doi: 10.1016/j.canlet.2012.10.003.	`Click`